The company encounters challenges in biologics manufacturing due to the complexity and higher costs compared to traditional small molecule compounds. The manufacturing process involves multiple components that require specialized knowledge and personnel. Scale-up timelines may be affected by material shortages, construction delays, and global supply chain disruptions influenced by health epidemics, geopolitical conflicts, and macroeconomic conditions. Biologics production is vulnerable to product loss from contamination, equipment failure, operator error, and variability in product characteristics. Some raw materials are biologically derived, difficult to procure, and may be subject to contamination or recall, potentially disrupting commercialization. Production requires substantial lead time, and changes in manufacturing methods during development carry risks of impacting product performance and clinical trial outcomes. The company depends on third parties for raw materials and may face challenges in obtaining adequate supplies. The international supply chain for products tarcocimab, KSI-501, and KSI-101 involves single-source suppliers located in China, Japan, the United Kingdom, the United States, and Switzerland. The company has limited manufacturing experience with its products.
Kodiak Sciences Inc's Comment on Supply Chain
The company encounters challenges in biologics manufacturing due to the complexity and higher costs compared to traditional small molecule compounds. The manufacturing process involves multiple components that require specialized knowledge and personnel. Scale-up timelines may be affected by material shortages, construction delays, and global supply chain disruptions influenced by health epidemics, geopolitical conflicts, and macroeconomic conditions. Biologics production is vulnerable to product loss from contamination, equipment failure, operator error, and variability in product characteristics. Some raw materials are biologically derived, difficult to procure, and may be subject to contamination or recall, potentially disrupting commercialization. Production requires substantial lead time, and changes in manufacturing methods during development carry risks of impacting product performance and clinical trial outcomes. The company depends on third parties for raw materials and may face challenges in obtaining adequate supplies. The international supply chain for products tarcocimab, KSI-501, and KSI-101 involves single-source suppliers located in China, Japan, the United Kingdom, the United States, and Switzerland. The company has limited manufacturing experience with its products.
Sources:
Kodiak Sciences Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Kodiak Sciences Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
